Clinically, treatment with SGLT2 inhibitors such as dapagliflozin has been associated with reduced AF incidence in patients with type 2 diabetes, supporting a potential role in atrial substrate modulation. The gene discussed is SLC5A2; the disease is atrial fibrillation.